![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Candida albicans, one of the pathogenic Candida species, causes high mortality rate in immunocompromised and high-risk surgical patients. In the last decade, only one new class of antifungal drug echinocandin was applied. The increased therapy failures, such as the one caused by multi-drug resistance, demand innovative strategies for new effective antifungal drugs. Synergistic combinations of antifungals and anti-virulence agents highlight the pragmatic strategy to reduce the development of drug resistant and potentially repurpose known antifungals, which bypass the costly and time-consuming pipeline of new drug development. Anti-virulence and synergistic combination provide new options for antifungal drug discovery by counteracting the difficulty or failure of traditional therapy for fungal infections.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Funding
This work was supported by China Ocean Mineral Resources R & D Association (Grant No. DY125-15-T-07) and the National Program on Key Basic Research Project (973 program, 2013CB734000), in part by grants from the National Natural Science Foundation of China [31430002, 31400090, 31320103911, 81302678 and 31125002], and the Ministry of Science and Technology of the People's Republic of China [2011ZX09102-011-11, 2013ZX10005004-005], LZ is an awardee for the National Distinguished Young Scholar Program in China.